ResQ Pharma's LipidRescue Receives FDA PDUFA Date for LAST Treatment
Key Insights
ResQ Pharma (search)'s LipidRescue Kit has been granted a PDUFA date of June 2, 2025, by the FDA, marking a significant step toward potential approval.
LipidRescue is designed as a drug/device combination to rapidly administer lipid emulsion, counteracting the toxicity of local anesthetics in LAST.
The LipidRescue Kit aims to standardize and simplify the treatment of LAST, offering a pre-packaged solution with clear instructions for healthcare providers.
ResQ Pharma (search), Inc. has announced that the FDA has set a Prescription Drug User Fee Act (PDUFA) date of June 2, 2025, for its LipidRescue Kit. This kit is designed to treat Local Anesthetic Systemic Toxicity (search) (LAST), a rare but potentially fatal condition that can arise from the use of local anesthetics like lidocaine. If approved, LipidRescue would be the first FDA-approved treatment specifically for LAST.
Addressing a Critical Unmet Need in Anesthesia
LAST is a life-threatening event characterized by symptoms such as altered mental status, cardiac instability, seizures, coma, respiratory or cardiac arrest, and potentially death. It can occur in various healthcare settings where local anesthetics are administered. Current treatment involves the infusion of lipid emulsion, a practice supported by clinical guidelines and extensive preclinical and clinical data. However, LipidRescue aims to improve upon this standard by providing a standardized, readily available kit.
LipidRescue: A Novel Drug-Device Combination
LipidRescue comprises a soybean oil emulsion to mitigate the toxic effects of local anesthetic overdose, along with a purpose-designed administration set. This set facilitates rapid and accurate administration of the lipid emulsion through existing vascular access, eliminating the need for needles to draw lipid from bags. The kit also includes a quick reference guide with clear instructions, crucial for timely intervention when seconds matter.
Expert Perspectives on LipidRescue
Dr. Guy Weinberg, Founder and President of ResQ Pharma (search) and the inventor of LipidRescue Therapy (LRT), stated, "Since discovering more than 25 years ago that lipid emulsion infusion could reverse catastrophic reactions to local anesthetics, I have looked forward to the day that this novel therapy would become a widely available, standardized treatment for a dangerous and potentially fatal condition."
The Significance of the PDUFA Date
The assignment of a PDUFA date signifies that the New Drug Application (NDA) is sufficiently complete for substantive review. This provides a timeline for when the review should be completed, marking a crucial milestone in the drug development process. Mukesh Kumar of FDAMap, who consulted on the NDA preparation, and Michael Gaba of Polsinelli's FDA practice group, are also key figures in ResQ Pharma (search)'s regulatory efforts.
ResQ Pharma's Vision for LipidRescue
ResQ Pharma (search) envisions LipidRescue as a means to ensure reliable, global use of LRT, not only for LAST but also potentially for other lipophilic drug overdoses and poisonings. The company, founded by Dr. Weinberg, is dedicated to commercializing his research findings on the mechanisms and treatment of local anesthetic toxicity.